作者： admin

Jamaica’s public health sector witnessed a significant enhancement on Monday with the donation of vital medical equipment worth over $34 million. Esteemed philanthropist Carol Picart, in partnership with the National Health Care Enhancement Foundation, contributed two ventilators valued at $11.57 million and an endoscopy unit, including a gastroscope and colonoscope, priced at $23 million. The ceremonial handover took place at Kingston Public Hospital (KPH). The donated equipment, which will also benefit Cornwall Regional and Black River hospitals, is expected to play a pivotal role in diagnosing and treating various medical conditions, including ulcers, gastritis, and colorectal issues. Picart emphasized her commitment to improving Jamaica’s life expectancy and reversing the declining birth rate, attributing these challenges to insufficient resources. She drew parallels to Maslow’s hierarchy of needs, highlighting her desire to give back to society. Recent data from the World Health Organization (WHO) underscores the urgency of such initiatives, revealing a decline in Jamaica’s life expectancy from 72.3 years in 2000 to 70.1 years in 2021. Additionally, the United Nations Population Fund (UNFPA) reports that Jamaica’s fertility rate has plummeted to 1.3 children per woman, well below the replacement level of 2.1. Krystal Lee, the junior minister of health and wellness, expressed profound gratitude for the donation, acknowledging the ongoing efforts to transform Jamaica’s healthcare system. She stressed the importance of public-private partnerships in bridging gaps in primary healthcare and called for continued collaboration to achieve national health goals. Lee also outlined the ministry’s plans to equip healthcare facilities with additional resources, emphasizing the critical role of health in fostering national development and prosperity.

In a significant move to combat the HIV epidemic, Jamaica’s Ministry of Health and Wellness is preparing to launch a pilot programme for lenacapavir, the first US Food and Drug Administration-approved injectable HIV prevention drug. This initiative, described by former US President Bill Clinton as a “genuine chance to end” the global HIV crisis, aims to provide a long-acting alternative to daily oral pills. Lenacapavir, administered twice a year, will be offered free of charge in Jamaica’s public health system, targeting vulnerable populations. Dr. Nicola Skyers, senior medical officer of the National HIV/STI programme, emphasized the drug’s potential to address adherence challenges, particularly among younger individuals less accustomed to daily pill regimens. The pilot will also include cabotegravir, another injectable pre-exposure prophylaxis (PrEP) taken every two months. While the cost of injectable antiretrovirals remains high, Jamaica is exploring partnerships to make these treatments more accessible. Lenacapavir, set for rollout in the US by year-end at $28,000 annually, will be available in 120 low- and middle-income countries by 2027 at a reduced cost of $40 per person, thanks to collaborations between the Clinton Health Access Initiative, the Gates Foundation, and Wits RHI. The World Health Organization has endorsed lenacapavir as a transformative preventive measure, with WHO Director-General Dr. Tedros Adhanom Ghebreyesus calling it “the next best thing” to an HIV vaccine. In Jamaica, where approximately 26,000 individuals live with HIV/AIDS, young adults have expressed enthusiasm for the injectable option, citing convenience and effectiveness over daily oral PrEP.

In 2022, France introduced a groundbreaking strategy to combat endometriosis, a chronic condition affecting one in ten women of reproductive age worldwide. Central to this initiative was the promotion of the ‘Endotest,’ a saliva-based diagnostic tool developed by French start-up Ziwig. Marketed as a revolutionary solution leveraging artificial intelligence and microRNA technology, the test promised to simplify and expedite the diagnosis of endometriosis, which currently requires invasive surgical procedures. However, despite significant government backing and financial investment, questions linger about the test’s efficacy and broader applicability. Researchers have raised concerns about the limited scope of studies supporting the Endotest, with some arguing that the participant samples may not be representative of the general population. While the French Health Authority (HAS) has acknowledged the test’s diagnostic performance, it has also called for further research to confirm its clinical utility. Critics have pointed out the disproportionate funding allocated to the Endotest compared to other endometriosis research avenues, such as improving ultrasound interpretation. Patient advocacy groups like Endomind have campaigned for broader access to the test, but some patients and experts remain skeptical, questioning whether the Endotest truly represents a significant advancement in endometriosis care. Ziwig’s leadership defends the test, citing published research and ongoing efforts to validate its effectiveness through peer-reviewed journals. As the debate continues, the Endotest remains a focal point in France’s broader efforts to address the challenges of diagnosing and treating endometriosis.